These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 17605572)

  • 1. What makes consumers think dietary supplements are safe and effective? The role of disclaimers and FDA approval.
    Dodge T; Kaufman A
    Health Psychol; 2007 Jul; 26(4):513-7. PubMed ID: 17605572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of the dietary supplement health and education act on consumer beliefs about the safety and effectiveness of dietary supplements.
    Dodge T; Litt D; Kaufman A
    J Health Commun; 2011 Mar; 16(3):230-44. PubMed ID: 21120738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ephedra: yesterday, DSHEA, and tomorrow--a ten year perspective on the Dietary Supplement Health and Education Act of 1994.
    Seamon MJ; Clauson KA
    J Herb Pharmacother; 2005; 5(3):67-86. PubMed ID: 16520299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can claims, misleading information, and manufacturing issues regarding dietary supplements be improved in the United States?
    Gibson JE; Taylor DA
    J Pharmacol Exp Ther; 2005 Sep; 314(3):939-44. PubMed ID: 15833895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dietary supplement adverse event reports: review and analysis.
    Talati AR; Gurnani AK
    Food Drug Law J; 2009; 64(3):503-13. PubMed ID: 19999641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA regulation of dietary supplements and requirements regarding adverse event reporting.
    Frankos VH; Street DA; O'Neill RK
    Clin Pharmacol Ther; 2010 Feb; 87(2):239-44. PubMed ID: 20032973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA perspectives on supplement use by patients on antithrombotic therapy: dietary supplement regulatory overview.
    Woo JJ
    Thromb Res; 2005; 117(1-2):193-6; discussion 201-7. PubMed ID: 16253311
    [No Abstract]   [Full Text] [Related]  

  • 8. Premarket notifications of new dietary ingredients--a ten-year review.
    McGuffin M; Young AL
    Food Drug Law J; 2004; 59(2):229-44. PubMed ID: 15318394
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulating dietary supplement safety under the dietary supplement health and education act: brave new world or pyrrhic victory?
    Silverglade BA
    Food Drug Law J; 1996; 51(2):319-21. PubMed ID: 11822324
    [No Abstract]   [Full Text] [Related]  

  • 11. Assessing supplement safety--the FDA's controversial proposal.
    Cohen PA
    N Engl J Med; 2012 Feb; 366(5):389-91. PubMed ID: 22276780
    [No Abstract]   [Full Text] [Related]  

  • 12. Protecting consumers in the wake of the U.S. Dietary Supplement Health and Education Act.
    Foote JC
    J Allied Health; 2007; 36(1):57-60. PubMed ID: 17425193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Dietary Supplement and Health Education Act and supplements: dietary and nutritional supplements need no more regulations.
    Wollschlaeger B
    Int J Toxicol; 2003; 22(5):387-90. PubMed ID: 14555412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure/function claims in dietary supplement labeling: not all of these claims need to be submitted to FDA and accompanied in labeling by the DSHEA disclaimer.
    McNamara SH
    Food Drug Law J; 1999; 54(1):35-42. PubMed ID: 11758558
    [No Abstract]   [Full Text] [Related]  

  • 15. Regulations on statements made for dietary supplements concerning the effect of the product on the structure or function of the body. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Jan; 65(4):1000-50. PubMed ID: 11010621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA perspectives on supplement use by patients on antithrombotic therapy.
    Kim MJ
    Thromb Res; 2005; 117(1-2):197-200; discussion 201-7. PubMed ID: 16188297
    [No Abstract]   [Full Text] [Related]  

  • 17. The importance of GRAS to the functional food and nutraceutical industries.
    Burdock GA; Carabin IG; Griffiths JC
    Toxicology; 2006 Apr; 221(1):17-27. PubMed ID: 16483705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re-thinking the dietary supplement laws and regulations 14 years after the Dietary Supplement Health and Education Act implementation.
    Jiang T
    Int J Food Sci Nutr; 2009 Jun; 60(4):293-301. PubMed ID: 19085198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From herbal Prozac to Mark McGwire's tonic: how the Dietary Supplement Health and Education Act changed the regulatory landscape for health products.
    Kaczka KA
    J Contemp Health Law Policy; 2000; 16(2):463-99. PubMed ID: 10970182
    [No Abstract]   [Full Text] [Related]  

  • 20. The Food and Drug Administration's actions on ephedra and androstenedione: understanding their potential impacts on the protections of the Dietary Supplement Health and Education Act.
    Siegner AW
    Food Drug Law J; 2004; 59(4):617-28. PubMed ID: 15880877
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 31.